Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Steno-2 — a small study with a big heart

Nature Reviews Endocrinology volume 12, pages 692–694 (2016)Cite this article

Subjects

In the Steno-2 trial, 160 individuals with type 2 diabetes mellitus, mostly in their 50s, were randomly assigned to multifactorial interventions or conventional care. Whereas microvascular and macrovascular complications were reduced during the 7.8 years of the trial period with intensive therapy, the observational follow-up data at 13.3 years and, now, 21 years demonstrate a benefit on mortality.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Forest plot of intervention trials exclusively performed in individuals with diabetes mellitus.

References

  1. Gæde, P. et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia http://dx.doi.org/10.1007/s00125-016-4065-6 (2016).

  2. Gubitosi-Klug, R. et al. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: The DCCT/EDIC study 30-year follow-up. Diabetes Care 39, 686–693 (2016).

    Article  Google Scholar 

  3. Holman, R. R. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).

    Article  CAS  Google Scholar 

  4. Gæde, P. et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358, 580–591 (2008).

    Article  Google Scholar 

  5. ACCORD Study Group. Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care 39, 701–708 (2016).

  6. Zoungas, S. et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 371, 1392–1406 (2014).

    Article  Google Scholar 

  7. Hayward, R. A. et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 372, 2197–2206 (2015).

    Article  CAS  Google Scholar 

  8. Cushman, W. C. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575–1585 (2010).

    Article  Google Scholar 

  9. Colhoun, H. M. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685–696 (2004).

    Article  CAS  Google Scholar 

  10. Wing, R. R. et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N. Engl. J. Med. 369, 145154 (2013).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. LMC Diabetes & Endocrinology, 2130 North Park Drive, Suite 238, Brampton, L6S 0C9, Ontario, Canada

    Harpreet Bajaj

  2. Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, 60 Murray Street, L5, Toronto, M5T 3L9, Ontario, Canada

    Harpreet Bajaj

  3. Division of Endocrinology, University of Toronto; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, 60 Murray Street, Suite L5-024, Mail BOX 17, Toronto, M5T 3L9, Ontario, Canada

    Bernard Zinman

Authors
  1. Harpreet Bajaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernard Zinman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernard Zinman.

Ethics declarations

Competing interests

H.B. has received consultancy fees or honoraria from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi-Aventis and Valeant, and grant support from Abbott, Astra Zeneca, Eli Lilly, Genkyotex, Merck, Novo Nordisk, Pfizer, Sanofi-Aventis and Valeant. B.Z. has received consultancy fees or honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi and Takeda, and grant support from Astra Zeneca, Boehringer Ingelheim and Novo Nordisk.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bajaj, H., Zinman, B. Steno-2 — a small study with a big heart. Nat Rev Endocrinol 12, 692–694 (2016). https://doi.org/10.1038/nrendo.2016.172

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2016.172

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing